LMAT — LeMaitre Vascular, Inc. stock price, charts and financials

QT38LeMaitre Vascular, Inc.

LeMaitre Vascular, Inc. (NASDAQ: LMAT) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
79.66
-1.79-2.20%
LMATQT38LeMaitre Vascular, Inc.·NASDAQ
79.66-2.20%
TA
Loading chart...
Signal & projected range
Earnings miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E28.09EPS (ttm)2.90Insider Own8.23%Shs Outstand22.85MPerf Week-19.61%
Market Cap1.86BForward P/E25.48EPS next Y3.20Insider Trans-14.88%Shs Float21.27MPerf Month-20.46%
Enterprise Value2.02BPEG0.74EPS next Q-Inst Own-Short Float6.96%Perf Quarter-24.52%
Income65.70MP/S7.09EPS this Y6.93%Inst Trans-Short Ratio4.94Perf Half Y-6.37%
Sales262.43MP/B4.43EPS next Y10.31%ROA10.25%Short Interest1.48MPerf YTD0.43%
Book/sh-P/C22.44EPS next 5Y-ROE16.42%52W High115.41 -30.98%Perf Year-12.64%
Cash/sh-P/FCF25.21EPS past 3/5Y39.41% 19.36%ROIC9.76%52W Low76.92 3.56%Perf 3Y25.89%
Dividend Est.1.00 (1.26%)EV/EBITDA20.81Sales past 3/5Y15.56% 14.15%Gross Margin72.90%Volatility5.29% 3.94%Perf 5Y49.56%
Dividend TTM0.90 (1.13%)EV/Sales7.72EPS Y/Y TTM40.41%Oper. Margin29.46%ATR (14)5.10Perf 10Y390.96%
Dividend Ex-DateAug 20, 2026Quick Ratio13.96Sales Y/Y TTM16.36%Profit Margin25.02%RSI (14)32.37Recom2.30
Dividend Gr. 3/5Y16.96% 16.05%Current Ratio16.31EPS Q/Q41.67%SMA20-16.71%Beta0.48Target Price115.00
Payout31.21%Debt/Eq0.45Sales Q/Q11.67%SMA50-15.51%Rel Volume1.04Prev Close81.45
Employees655LT Debt/Eq0.46EarningsNov 05SMA200-14.87%Avg Volume361.10KPrice79.66
IPO DateOct 19, 2006Option/ShortYes / YesEPS/Sales Surpr.2.93% -0.18%Net Debt/EBITDA1.68Volume374,422Change-2.20%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-06-26ReiteratedBarringtonOutperform$120$95
May-06-26ReiteratedLake StreetBuy$110$135
May-06-26ReiteratedBarrington ResearchOutperform$120
Nov-10-25ReiteratedCantor FitzgeraldNeutral$96$95
Nov-05-25ResumedRoth CapitalBuy$108
Aug-06-25UpgradeBarrington ResearchMarket PerformOutperform
Feb-28-25ReiteratedLake StreetBuy$110
Feb-28-25DowngradeBarrington ResearchOutperformMarket Perform
Oct-15-24InitiatedCantor FitzgeraldNeutral$96
Aug-20-24ReiteratedJMP SecuritiesMarket Outperform$100
Latest News
Aug-06-26
Aug-05-26
Aug-04-26
04:05PM
Jul-29-26
Jul-14-26
Jun-24-26
Jun-18-26
Company

Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue262250220
Cost of Goods Sold Incl. D&A717169
Gross Profit191179151
Selling, General and Administrative Excl. Other1009683
Research and Development161416
Other Operating Expense-210
Operating Income776852
Interest Expense450
Unusual Expense
Non-Operating Income (Expense)13125
Net Income Before Taxes857557
Income Taxes191713
Consolidated Net Income665844
Net Income From Continuing Operations665844
Net Income665844
EPS (Recurring)2.902.551.96
EPS (Basic, Before Extraordinaries)2.902.551.96
EPS (Diluted)2.852.521.93
EBITDA979167
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio27.9532.1847.74
Price To Sales Ratio6.997.469.21
Gross Margin72.9071.6068.64
Operating Margin29.3927.2023.64
Net Margin25.1923.2020.00
Shares Outstanding232322
Market Capitalization1,8321,8652,027
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$123.15$110.67$98.19$85.72$73.24 Close Price0.00M4.26M8.52M12.77M17.03MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Kamke Trent GSenior V. P., OperationsMay 08 '26Sale107.002,928313,2873,749May 11
LeMaitre George WChairman and CEOMay 08 '26Sale108.6927,8813,030,4001,430,019May 11
Ross Bridget ADirectorMay 07 '26Option Exercise48.155,044242,8828,986May 11
Ross Bridget ADirectorMay 07 '26Sale111.105,044560,3663,942May 11
Jasinski Lawrence JDirectorMay 07 '26Option Exercise65.922,858188,4128,657May 11
Jasinski Lawrence JDirectorMay 07 '26Sale110.003,943433,7304,714May 11
LeMaitre George WChairman and CEOMay 07 '26Sale107.6418,6002,002,0131,457,900May 11
Pellegrino Joseph P JRDirectorApr 22 '26Option Exercise35.482,941104,34715,021Apr 23
Kamke Trent GSenior V. P., OperationsMar 11 '26Sale108.502,625284,8136,677Mar 13
Roberts David BPresident and DirectorMar 11 '26Sale107.683,312356,58614,667Mar 13
Kamke Trent GSenior V. P., OperationsMar 11 '26Option Exercise35.482,62593,1359,302Mar 13
LeBlanc Dorian PaulChief Financial OfficerMar 10 '26Option Exercise0.00202,400Mar 12
LeMaitre George WChairman and CEOMar 02 '26Sale107.8155,9306,030,0201,476,500Mar 02
Kamke Trent GSenior V. P., OperationsFeb 27 '26Sale110.291,044115,1436,677Mar 02
Roberts David BPresident and DirectorFeb 27 '26Sale106.808,464903,95817,979Mar 02
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.